Paper1968358
Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
Ford JM and 4 others. Cancer Res, 1990. Cited by 147 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Papers, record 1968358. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1968358
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Resistance | Major topic |
| Membrane Glycoproteins | Major topic |
| Thioxanthenes | Major topic |
| ATP Binding Cassette Transporter, Subfamily B, Member 1 | |
| Animals | |
| Breast Neoplasms | |
| Calmodulin | |
| Cell Division | |
| Cell Line | |
| Cell Membrane | |
| Cells, Cultured | |
| Humans | |
| KB Cells | |
| Mice | |
| Neoplasm Proteins | |
| Protein Kinase C | |
| Structure-Activity Relationship | |
| Tumor Cells, Cultured |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA43888-03 | NCI NIH HHS | United States | PubMed | PubMed | |
| P01 CA08341-25 | NCI NIH HHS | United States | P01CA083412 | PubMed | NIH RePORTER |
| P01CA008341 | NIH | NIH RePORTER | |||
| R01CA043888 | NIH | NIH RePORTER |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 147 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38524477 | Intramolecular Friedel-Crafts Reaction with Trifluoroacetic Acid: Synthesizing Some New Functionalized 9-Aryl/Alkyl Thioxanthenes. | ACS Omega | 2024 | https://conductscience.org/library/papers/38524477 | PubMed |
| 30813251 | The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30813251 | PubMed |
| 25801244 | Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells. | Tumour Biol | 2015 | https://conductscience.org/library/papers/25801244 | PubMed |
| 24944704 | Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells. | Oncol Lett | 2014 | https://conductscience.org/library/papers/24944704 | PubMed |
| 24641346 | Multilayer spheroids to quantify drug uptake and diffusion in 3D. | Mol Pharm | 2014 | https://conductscience.org/library/papers/24641346 | PubMed |
| 23973912 | Nanopreparations to overcome multidrug resistance in cancer. | Adv Drug Deliv Rev | 2013 | https://conductscience.org/library/papers/23973912 | PubMed |
| 22363694 | High glucose decreases expression and activity of p-glycoprotein in cultured human retinal pigment epithelium possibly through iNOS induction. | PLoS One | 2012 | https://conductscience.org/library/papers/22363694 | PubMed |
| 20520719 | Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. | PLoS One | 2010 | https://conductscience.org/library/papers/20520719 | PubMed |
| 19533022 | Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil. | Invest New Drugs | 2010 | https://conductscience.org/library/papers/19533022 | PubMed |
| 18945821 | Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. | Mol Pharmacol | 2009 | https://conductscience.org/library/papers/18945821 | PubMed |
| 18493718 | Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R). | Invest New Drugs | 2009 | https://conductscience.org/library/papers/18493718 | PubMed |
| 14586208 | Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells. | Invest New Drugs | 2003 | https://conductscience.org/library/papers/14586208 | PubMed |
| 12543683 | Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. | Antimicrob Agents Chemother | 2003 | https://conductscience.org/library/papers/12543683 | PubMed |
| 11934808 | Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins. | Br J Pharmacol | 2002 | https://conductscience.org/library/papers/11934808 | PubMed |
| 11434876 | Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. | Breast Cancer Res | 2001 | https://conductscience.org/library/papers/11434876 | PubMed |
| 9380680 | Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. | Proc Natl Acad Sci U S A | 1997 | https://conductscience.org/library/papers/9380680 | PubMed |
| 8738607 | Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. | Breast Cancer Res Treat | 1996 | https://conductscience.org/library/papers/8738607 | PubMed |
| 8546900 | MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8546900 | PubMed |
| 8543589 | Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. | J Cancer Res Clin Oncol | 1996 | https://conductscience.org/library/papers/8543589 | PubMed |
| 8431967 | Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8431967 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| CALM1 | 801 | PubTator's text mining | https://conductscience.org/library/genes/801 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1968358
GET https://conductscience.org/api/papers/v1/1968358/cited_by?page=2